Male Infertility – Pipeline Review, H2 2018: Featuring Cadila Healthcare and Health Ever Bio-Tech – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Male
Infertility – Pipeline Review, H2 2018”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Male Infertility – Pipeline Review, H2 2018, provides
comprehensive information on the therapeutics under development for Male
Infertility (Male Health), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Male Infertility (Male Health) pipeline guide also reviews of key
players involved in therapeutic development for Male Infertility and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies/Universities/Institutes, the
molecules developed by Companies in Phase II, Phase I, Preclinical and
Discovery stages are 2, 2, 1 and 3 respectively. Similarly, the
Universities portfolio in Preclinical and Discovery stages comprises 2
and 1 molecules, respectively.

This pipeline guide helps in identifying and tracking emerging players
in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.

Companies Featured

  • Cadila Healthcare Ltd.
  • Health Ever Bio-Tech Co. Ltd.

Key Topics Covered

1. Introduction

2. Report Coverage

3. Male Infertility – Overview

4. Male Infertility – Therapeutics Development

5. Pipeline Overview

6. Pipeline by Companies

7. Pipeline by Universities/Institutes

8. Products under Development by Companies

9. Products under Development by Universities/Institutes

10. Male Infertility – Therapeutics Assessment

11. Male Infertility – Companies Involved in Therapeutics Development

12. Male Infertility – Drug Profiles

13. Male Infertility – Dormant Projects

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rlctsj/male_infertility?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Sexual
and Reproductive Health Drugs